Naturland Holding Zrt's revenue for the
six
months ended in Jun. 2025 was Ft3,184 Mil.
Its revenue for the trailing twelve months (TTM) ended in Jun. 2025 was Ft6,322 Mil.
Naturland Holding Zrt's Revenue per Share for the
six
months ended in Jun. 2025 was Ft230.42.
Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2025 was Ft457.61.
During the past 5 years, Naturland Holding Zrt's highest 3-Year average Revenue per Share Growth Rate was 201.30% per year. The lowest was 8.20% per year. And the median was 104.75% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BUD:NATURLAND vs ZTS, UTHR, VTRS: Revenue Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Naturland Holding Zrt's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Naturland Holding Zrt Revenue vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Naturland Holding Zrt's Revenue distribution charts can be found below:
* The bar in red indicates where Naturland Holding Zrt's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Jun. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was Ft6,322 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Naturland Holding Zrt (BUD:NATURLAND) has a Revenue of Ft6,322 Mil as of Jun. 2025. Revenue is the total amount a company generates as sales through its operations. View historical data on Naturland Holding Zrt and its competitors.
Is Naturland Holding Zrt's Revenue too high?
Naturland Holding Zrt's current Revenue is Ft6,322 Mil. Overall, Naturland Holding Zrt has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Naturland Holding Zrt's Revenue compare to ZTS and UTHR?
Naturland Holding Zrt's Revenue of Ft6,322 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Drug Manufacturers company?
A good Revenue depends on the Drug Manufacturers industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Naturland Holding Zrt and its competitors. Naturland Holding Zrt's current Revenue is Ft6,322 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Naturland Holding Zrt stock overvalued right now?
Based on GuruFocus' analysis, Naturland Holding Zrt (BUD:NATURLAND) is currently considered Fairly Valued. The stock's GF Value™ is Ft2,882.33, compared to a current price of Ft2,820.00 — trading 2.2% below its estimated fair value. The current Revenue is Ft6,322 Mil. Naturland Holding Zrt's overall GF Score™ is 61/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Naturland Holding Zrt (BUD:NATURLAND), the current Revenue is Ft6,322 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Naturland Holding Zrt (BUD:NATURLAND) Overvalued in 2026?
Based on GuruFocus' analysis, Naturland Holding Zrt stock appears to be undervalued.
The current stock price of Ft2,820.00 is trading 2.2% below its estimated GF Value™ of Ft2,882.33.
GuruFocus considers Naturland Holding Zrt to be Fairly Valued.
Key valuation signals for BUD:NATURLAND:
Revenue: Ft6,322 Mil
GF Value™: Ft2,882.33 vs. price of Ft2,820.00 (2.2% below fair value)
No single metric tells the full story. See the BUD:NATURLAND stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Naturland Holding Zrt thro9ugh its subsidiaries engage in the production of pharmaceutical products. It engages in the development, production, and wholesale of dietary supplements and cosmetics, herbal medicine, teas, and essential oils. The firm offers tablets, suppositories, ointments, and ophthalmic base solutions.
61GF Score
Get the complete analysis for BUD:NATURLAND
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BUD:NATURLAND has been successfully added to your 
